Mexico - Delayed Quote MXN

RECURSION PHARMACEUTICALS INC (RXRX.MX)

124.00

0.00

(0.00%)

As of March 11 at 11:00:43 AM CST. Market Open.

Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025

Salt Lake City, UT, April 22, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, will present preliminary data during the 2025 Digestive Disease Week (DDW) meeting from its ongoing Phase 1b/2 clinical trial, TUPELO, which is evaluating the safety and preliminary activity of REC-4881 for the treatment of familial adenomatous polyposis (FAP). The data will be presented as a late-breaking oral presentation during

GlobeNewswire yesterday

RXRX
Recursion Pharmaceuticals (NasdaqGS:RXRX) Taps Real-World Data With HealthVerity Licensing Deal

Recursion Pharmaceuticals (NasdaqGS:RXRX) recently announced a licensing agreement to integrate HealthVerity's extensive real-world data into its platforms. In the same week, Recursion reported significant advancements in its drug discovery initiatives and clinical studies, including dosing the first patient in a promising Phase 1 trial. Despite the broader market's flat performance over the past week, Recursion's stock price saw a 22% increase, suggesting that these developments reinforced...

Simply Wall St. 6 days ago

RXRX
HealthVerity Partners with Recursion to Enhance Clinical Trial Analytics with Real-World Data

HealthVerity, the leader in real-world data (RWD) technology and privacy-compliant data exchange, today announced that Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, has licensed its real-world data to enhance clinical trial design and analytics.

PR Newswire 8 days ago

RXRX
Recursion Pharma rises, Intel & Five Below fall: Trending Tickers

Julie Hyman and Josh Lipton take a closer look at some of today's trending tickers. Recursion Pharma (RXRX) stock surges after the Food and Drug Administration (FDA) announced plans to phase out some animal testing requirements. Intel (INTC) stock falls as tensions in the US-China trade war intensify. Five Below (FIVE) stock declines as China tariffs impact orders. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.

Yahoo Finance Video 12 days ago

INTC

RXRX

FIVE
Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries

Kyiv, Ukraine and Salt Lake City, UT, April 09, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced the generation of screening libraries leveraging tools within its AI/ML platform, the Recursion OS, with Enamine's REAL Space, the world’s largest source of make-on-demand small molecules. Together, the two companies have curated 10 enriched screening libraries from over 15,000 newly synthesized co

GlobeNewswire 15 days ago

RXRX
$Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas$

Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas

REC-3565 is a potential best-in-class MALT1 inhibitor for multiple hematology indications, designed to reduce the risk of hyperbilirubinemia, a common side effect of other MALT1 inhibitorsSalt Lake City, UT, April 08, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that the first patient has been dosed in the Phase 1 EXCELERIZE clinical study evaluating REC-3565 for the treatment of relapsed

GlobeNewswire 16 days ago

RXRX
Recursion Pharmaceuticals (NasdaqGS:RXRX) Sees 27% Weekly Drop After Leadership Changes

Recursion Pharmaceuticals (NasdaqGS:RXRX) witnessed a 27% decline in market value over the last week, a period marked by significant Executive and Board changes. The company appointed Dr. Namandjé Bumpus and Elaine Sun to its Board, bolstering its leadership with extensive experience in regulatory science and the financial sector. Concurrently, the global equity markets endured a heavy sell-off, with the Nasdaq entering bear market territory and posting a 10% weekly decline, largely driven by...

Simply Wall St. 18 days ago

RXRX
Recursion to Participate in Upcoming Investor Conference

Salt Lake City, UT, April 01, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today its participation in the following upcoming investor conference: Needham 24th Annual Virtual Healthcare Conference — Monday, April 7, 2025 Webcasts may be found in the events section of the Recursion Investor Relations website at ir.recursion.com. About RecursionRecursion (NASDAQ: RXRX) is a clinical stage Tech

GlobeNewswire 23 days ago

RXRX
Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market Today

In the closing of the recent trading day, Recursion Pharmaceuticals (RXRX) stood at $6.48, denoting a -1.52% change from the preceding trading day.

Zacks last month

RXRX

^GSPC
Recursion Pharmaceuticals (NasdaqGS:RXRX) Jumps 12% Following US$500M Equity Offering

Recursion Pharmaceuticals (NasdaqGS:RXRX) saw its stock price increase by 12% over the past week. This movement could be associated with several recent developments. The company announced a significant follow-on equity offering of $500 million, which may have attracted investor attention. Additionally, Recursion’s reported earnings for FY 2024 showed growth in sales and revenue despite a widening net loss, providing mixed signals to the market. These strategic maneuvers coincided with broader...

Simply Wall St. last month

RXRX
Why Recursion Pharmaceuticals (RXRX) Went Up on Monday?

We recently published a list of 10 Firms Kick Off Monday Leading Gains. In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against other firms that kick off Monday leading gains. The stock market kicked off the week’s trading on a positive note, with all main indices […]

Insider Monkey last month

RXRX

NVDA
Recursion Bolsters Board of Directors with Former FDA Principal Deputy Commissioner Dr. Namandjé Bumpus and Mammoth Biosciences COO and CFO Elaine Sun

Dr. Bumpus brings deep experience in scientific innovation and regulatory strategy, while Elaine Sun adds extensive leadership in life sciences finance and corporate strategy.Salt Lake City, UT, March 18, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that Namandjé Bumpus, Ph.D, and Elaine Sun have been appointed to Recursion’s Board of Directors, effective as of March 15th.“I am delighted t

GlobeNewswire last month

RXRX
Big tech meets biotech: Recursion and the AI gold rush in pharma

As AI reshapes drug discovery and development, Recursion Pharmaceuticals is tapping into its potential.

Pharmaceutical Technology last month

RXRX
Why Recursion Pharmaceuticals Stock Is Sinking Today

Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) were sinking 8.2% lower as of 10:57 a.m. ET on Monday. The clinical-stage biotech company, which is a pioneer in using artificial intelligence (AI) in drug discovery, didn't announce any news that would cause its stock to fall, though. Part of the reason Recursion's shares tumbled is that the overall stock market has retreated as investors worried that the Trump administration's tariffs could cause an economic recession.

Motley Fool last month

RXRX

NVDA
Is This Beaten-Down Artificial Intelligence (AI) Stock a Buy?

Let's look at an AI-focused biotech company: Recursion Pharmaceuticals (NASDAQ: RXRX). The stock has significantly lagged the market in the past year, but if Recursion's ambitions become a reality, it could offer market-crushing returns from here on out. To understand Recursion's business, here are some basic facts about the grueling, expensive, and risky activity of developing and commercializing new medicines.

Motley Fool last month

RXRX
4 Things You Need to Know if You Buy Recursion Pharmaceuticals Stock Today

Investors looking for an exciting clinical-stage biotech start-up with enormous potential should be paying close attention to Recursion Pharmaceuticals (NASDAQ: RXRX). The company has emerged as a leader in drug discovery, enabled by artificial intelligence (AI) and a unique platform that it believes could revolutionize medicine. Here are four things you should know if you're thinking of buying Recursion Pharmaceuticals stock.

Motley Fool last month

RXRX
This Biotech Stock Could Be the Best Investment of the Decade

The term "game-changing" is overused for too many up-and-coming companies, but in this case, the description fits.

Motley Fool last month

RXRX
Down Over 40%, Is Recursion Pharmaceuticals a Buy on the Dip?

One corner of the economy where investors expect another big leap forward is the world of drug development. For every commercial-stage drug out there that generates millions and sometimes billions in annual sales, there were thousands of new drug candidates that didn't get across the finish line. Recursion Pharmaceuticals (NASDAQ: RXRX) has gained a lot of attention in recent years with an AI-powered drug-discovery platform that aims to reduce the amount of trial and error that's required to discover successful new drug candidates.

Motley Fool last month

RXRX
News Flash: Analysts Just Made A Sizeable Upgrade To Their Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Forecasts

Recursion Pharmaceuticals, Inc. ( NASDAQ:RXRX ) shareholders will have a reason to smile today, with the analysts...

Simply Wall St. last month

RXRX
Why Recursion Pharmaceuticals, Inc. (RXRX) Crashed on Monday

We recently published an article titled Trade Tensions Weigh Heavily on 10 Stocks. In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against the other stocks. The stock market kicked off the trading week in a bloodbath, erasing last week’s gains, with all major indices posting heavy losses […]

Insider Monkey last month

RXRX

ROG.SW

Performance Overview

Return	RXRX.MX	S&P 500 (^GSPC)
YTD	-38.00%	-6.80%
1-Year	-38.00%	+8.08%
3-Year	-38.00%	+28.32%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

RECURSION PHARMACEUTICALS INC (RXRX.MX)

Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025

Recursion Pharmaceuticals (NasdaqGS:RXRX) Taps Real-World Data With HealthVerity Licensing Deal

HealthVerity Partners with Recursion to Enhance Clinical Trial Analytics with Real-World Data

Recursion Pharma rises, Intel & Five Below fall: Trending Tickers

Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries

Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas

Recursion Pharmaceuticals (NasdaqGS:RXRX) Sees 27% Weekly Drop After Leadership Changes

Recursion to Participate in Upcoming Investor Conference

Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market Today

Recursion Pharmaceuticals (NasdaqGS:RXRX) Jumps 12% Following US$500M Equity Offering

Why Recursion Pharmaceuticals (RXRX) Went Up on Monday?

Recursion Bolsters Board of Directors with Former FDA Principal Deputy Commissioner Dr. Namandjé Bumpus and Mammoth Biosciences COO and CFO Elaine Sun

Big tech meets biotech: Recursion and the AI gold rush in pharma

Why Recursion Pharmaceuticals Stock Is Sinking Today

Is This Beaten-Down Artificial Intelligence (AI) Stock a Buy?

4 Things You Need to Know if You Buy Recursion Pharmaceuticals Stock Today

This Biotech Stock Could Be the Best Investment of the Decade

Down Over 40%, Is Recursion Pharmaceuticals a Buy on the Dip?

News Flash: Analysts Just Made A Sizeable Upgrade To Their Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Forecasts

Why Recursion Pharmaceuticals, Inc. (RXRX) Crashed on Monday

Performance Overview